Magnevist

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Renal InsufficiencyMeniere Disease

119 competitors in Renal Insufficiency

#DrugCompanyPhaseTrials

1

Galvus

Novartis

Phase 3

42

Afinitor

Novartis

Phase 3

13

Januvia

ZZydus Therapeutics Inc.

Phase 3

24

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

15

Calcineurin Inhibitors

Sanofi

Phase 3

16

Cysteine Hydrochloride

Novartis

Phase 2

17

Velcade

SShilpa Grover, MD, MPH

Phase 2

28

Decadron

AAspen Global Incorporated

Phase 2

29

Sarclisa

AAzienda U.S.L. 1 di Massa e Carrara

Phase 2

110

Tuoyi

CCoherus Oncology, Inc.

Phase 2

1Show 33 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

ART4 trials

A Comparison of Indirect and Direct MR Arthrography of the Shoulder Using Arthroscopic Correlation

Withdrawn·MMilton S. Hershey Medical Center·N/A·NCT01416740

Magnevist® Injection Enhanced MRA at Two Dose Levels Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Infrarenal Aorta and Peripheral Arteries

Completed·Bayer·Phase 3·NCT00185276·365 enrolled

Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis in the Calf and/or Pedal Arteries

Completed·Bayer·Phase 3·NCT00309075·126 enrolled

Show 1 more trial

Magnevist® Injection-enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis of the Renal Arteries

Completed·Bayer·Phase 3·NCT00310557·116 enrolled

MPA2 trials

Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Magnetic Resonance Angiography

Completed·Bayer·Phase 2·NCT00652418·12 enrolled

Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Aortic Arch and Cerebral Branches

Completed·Bayer·Phase 3·NCT00310609·123 enrolled

Meniere disease1 trial

Unilateral Meniere Disease: Can Double Dose Gadolinium and Delayed Imaging Make the Diagnosis?

Withdrawn·EEmory University·N/A·NCT02371798

Contrast Agent1 trial

Crossover Comparison of Two Gadolinium Contrast Agents for Use With MRA of Carotid, Renal and Peripheral Arteries

Completed·BBracco Diagnostics, Inc·Phase 3·NCT01260636·120 enrolled

Metastases1 trial

Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases

Completed·SStanford University·Phase 2·NCT00375830·114 enrolled

4 more indications

Cardiovascular1 trial

Cardiovascular Safety Study of Magnevist® Injection at Two Dose Levels and Two Injection Rates in Normal Subjects

Completed·Bayer·Phase 1·NCT00310596·71 enrolled

Children1 trial

Contrast-enhanced MRI in Children 2 Months to <2 Years

Completed·Bayer·Phase 3·NCT00937391·54 enrolled

Renal insufficiency1 trial

Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist

Completed·Bayer··NCT00744939·168 enrolled

Unspecified2 trials

Gadobutrol Magnevist-controlled Body Study

Completed·Bayer·Phase 3·NCT01050829·370 enrolled

Magnevist Post-marketing Surveillance in Japan

Completed·Bayer··NCT01376739·2,051 enrolled

Regulatory

FDA Approval Timeline[4]

Details

Drug Info

Related News